APA

Pless M., Belhadj K., Menssen H. D., Kern W., Coiffier B., Wolf J., Herrmann R., Thiel E., Bootle D., Sklenar I., Müller C., Choi L., Porter C. & Capdeville R. (20041019). Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Pless Miklos, Belhadj Karim, Menssen Hans D, Kern Wolfgang, Coiffier Bertrand, Wolf Jürgen, Herrmann Richard, Thiel Eckhard, Bootle Doug, Sklenar Ivo, Müller Christian, Choi Les, Porter Carl and Capdeville Renaud. 20041019. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Pless M., Belhadj K., Menssen H. D., Kern W., Coiffier B., Wolf J., Herrmann R., Thiel E., Bootle D., Sklenar I., Müller C., Choi L., Porter C. and Capdeville R. (20041019). Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Pless Miklos, Belhadj Karim, Menssen Hans D, Kern Wolfgang, Coiffier Bertrand, Wolf Jürgen, Herrmann Richard, Thiel Eckhard, Bootle Doug, Sklenar Ivo, Müller Christian, Choi Les, Porter Carl and Capdeville Renaud. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20041019.